Historique
Périodique
Males and females differ in response to opioid agonist medications
(Hommes et femmes diffèrent dans leur réponse aux traitements antagonistes opiacés)
Auteur(s) :
JONES, H. E. ;
FITZGERALD, H. ;
JOHNSON, R. E.
Année
2005
Page(s) :
223-233
Langue(s) :
Anglais
Refs biblio. :
47
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
SEXE
;
ANTAGONISTE
;
OPIACES
;
PHARMACOTHERAPIE
;
COMPARAISON
;
EFFICACITE
;
RETENTION
;
OBSERVANCE DU TRAITEMENT
Note générale :
American Journal on Addictions, 2005, 14, (3), 223-233
Note de contenu :
tabl.
Résumé :
ENGLISH :
Few clinical trials include sex as a factor. This analysis explored within-sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within-subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes. (Review' s abstract)
Affiliation :
Center for Addiction and Pregnancy, D-3 East, Johns Hopkins Bayview Medical Center, 4940 Eastern Av., Baltimore, MD 21224 ; hendreejonesyahoo.com
Etats-Unis. United States.
Etats-Unis. United States.